Seminars in Oncology
Volume 33 , Pages 33-38 , April 2006

Unresolved Issues in the Chemotherapeutic Management of Gynecologic Malignancies

  • Maurie Markman

      Affiliations

    • Dr Markman has received honoraria from Eli Lilly and Company for speaking engagements and for participation in medical advisory boards.
    • Corresponding Author InformationAddress reprint requests to Maurie Markman, MD, University of Texas M.D. Anderson Cancer Center, Mail box #121, 1515 Holcombe Blvd, Houston, TX 77030, USA

References 

  1. Ozols RF , Bundy BN , Greer BE , et al.   Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer (A Gynecologic Oncology Group study) . J Clin Oncol . 2003;21:3194–3200
  2. duBois A , Luck HJ , Meier W , et al.   A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer . J Natl Cancer Inst . 2003;95:1320–1329
  3. Vassey PA , Jayson GC , Gordon A , et al.   Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma . J Natl Cancer Inst . 2004;96:1682–1691
  4. Randall ME , Brunetto G , Muss HB , et al.   Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma (A randomized phase III trial of the Gynecologic Oncology Group) . Proc Am Soc Clin Oncol . 2003;22:2; (abstr)
  5. Green JA , Kirwan JM , Tierney JF , et al.   Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix (A systemic review and meta-analysis) . Lancet . 2001;358:781–786
  6. Trimbos JB , Parmar M , Vergote I , et al.   International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial (Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma) . J Natl Cancer Inst . 2003;95:105–112
  7. Markman M . Informing patients with cancer of “new findings” that may influence their willingness to participate in research studies . Cancer . 2003;98:885–887
  8. Bell J , Brady M , Lage J , et al.   A randomized phase III trial of three versus six cycles of carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma (A Gynecologic Oncology Group study) . Gynecol Oncol . 2003;88:156; (abstr)
  9. Markman M . Can we do a better job preventing clinically-relevant peripheral neuropathy resulting from carboplatin/paclitaxel chemotherapy? . Cancer Invest . 2004;22:471–473
  10. Markman M , Kennedy A , Webster K , et al.   Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum . J Clin Oncol . 2001;19:1901–1905
  11. Markman M , Liu PY , Wilczynski S , et al.   Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer who attained a clinically-defined complete response to platinum/paclitaxel-based chemotherapy (A Southwest Oncology Group and Gynecologic Oncology Group trial) . J Clin Oncol . 2003;21:2460–2465
  12. Gore M , Fryatt I , Wiltshaw E , et al.   Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds . Gynecol Oncol . 1990;36:207–211
  13. Markman M , Rothman R , Hakes T , et al.   Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin . J Clin Oncol . 1991;9:389–393
  14. Markman M , Kennedy A , Webster K , et al.   Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens . Gynecol Oncol . 1997;65:434–436
  15. Parmar MK , Ledermann JA , Colombo N , et al.   Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer (The ICON4/AGO-OVAR-2.2 trial) . Lancet . 2003;361:2099–2106
  16. Pfisterer J , Plante M , Vergote K , et al.   Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG . J Clin Oncol . 2004;22:14; (abstr)
  17. Markman M , Bookman MA . Second-line treatment of ovarian cancer . Oncologist . 2000;5:26–35
  18. Alberts DS , Liu PY , Hannigan EV , et al.   Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer . N Engl J Med . 1996;335:1950–1955
  19. Markman M , Bundy BN , Alberts DS , et al.   Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma (An Intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group and Eastern Cooperative Oncology Group) . J Clin Oncol . 2001;19:1001–1007
  20. Armstrong DS , Bundy BN , Baergen R , et al.   Randomized phase III study of intravenous paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC) (A Gynecologic Oncology Group trial) . Proc Am Soc Clin Oncol . 2002;21:201; (abstr 803)
  21. Fujiwara K , Markman M , Morgan M . Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer . Gynecol Oncol . 2005;97:10–15
  22. Fleming GF , Brunetto VL , Cella D , et al.   Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma (A Gynecologic Oncology Group study) . J Clin Oncol . 2004;22:2159–2166
  23. Hoskins P , Swenerton K , Pike J , et al.   Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer (A phase II study) . J Clin Oncol . 2001;19:4048–4053
  24. Scudder SA , Liu PY , Wilczynski SP , et al.   Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma (A phase II study of the Southwest Oncology Group) . Gynecol Oncol . 2005;96:610–615
  25. Markman M . Chemotherapeutic management of recurrent/metastatic uterine carcinosarcomas (malignant mixed mullerian tumors) (Time for a re-appraisal?) . J Cancer Res Clin Oncol . 2004;130:645–648
  26. Silverberg SG , Major FJ , Blessing JA , et al.   Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus (A Gynecologic Oncology Group pathologic study of 203 cases) . Int J Gynecol Pathol . 1990;9:1–19
  27. Moore DH , Blessing JA , McQuellon RP , et al.   Phase III study of cisplatin, with or without paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix (A Gynecologic Oncology Group study) . J Clin Oncol . 2004;22:3113–3119
  28. Long HJ , Bundy BN , Grendys EC , et al.   Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix (A Gynecologic Oncology Group study) . J Clin Oncol . 2005;23:4626–4633
  29. Hurwitz H , Fehrenbacher L , Novotny W , et al.   Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer . N Engl J Med . 2004;350:2335–2342
  30. Monk BJ , Huang HQ , Cella D , et al.   Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix? A Gynecologic Oncology Group study . J Clin Oncol . 2005;23:4617–4625

PII: S0093-7754(06)00120-5

doi: 10.1053/j.seminoncol.2006.03.013

Seminars in Oncology
Volume 33 , Pages 33-38 , April 2006

Article Tools